Young Jonathan R, Coy Heidi, Kim Hyun J, Douek Michael, Lo Pechin, Pantuck Allan J, Raman Steven S
1 Department of Radiology, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Ste 1638, Los Angeles, CA 90095-7437.
2 Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
AJR Am J Roentgenol. 2017 Apr;208(4):812-819. doi: 10.2214/AJR.16.17152. Epub 2017 Jan 26.
The objective of our study was to investigate the performance of relative enhancement on multiphasic MRI to differentiate clear cell renal cell carcinoma (RCC) from other RCC subtypes (papillary and chromophobe) and oncocytoma.
For this study, we derived a cohort of 34 clear cell RCCs, nine oncocytomas, 12 papillary RCCs, and 10 chromophobe RCCs with a preoperative multiphasic dynamic contrast-enhanced MRI study with up to four phases (i.e., unenhanced, corticomedullary, nephrographic, excretory) from 2005 to 2016. These groups were evaluated for multiphasic enhancement and were compared using Kruskal-Wallis and Mann-Whitney tests. ROC curves were constructed and logistic regression analyses were performed to evaluate the performance of multiphasic enhancement in differentiating clear cell RCCs from the other three groups.
Clear cell RCCs exhibited significantly greater relative signal intensity compared with uninvolved renal cortex in the corticomedullary phase (mean, 2.9) than oncocytomas (-21.7, p = 0.001), papillary RCCs (-53.0, p < 0.001), and chromophobe RCCs (-21.0, p < 0.001). Relative signal intensity in the corticomedullary phase differentiated clear cell RCCs from oncocytomas with an AUC of 0.90 and with an accuracy of 84% (32/38), sensitivity of 90% (27/30), and specificity of 63% (5/8) after controlling for lesion size, patient age, and patient sex. Relative corticomedullary signal intensity differentiated clear cell RCCs from oncocytomas and other RCC subtypes with an AUC of 0.93 and with an accuracy of 90% (53/59), sensitivity of 90% (27/30), and specificity of 90% (26/29) after controlling for lesion size, patient age, and patient sex.
Multiphasic MRI enhancement may assist in differentiating clear cell RCC from oncocytomas and other RCC subtypes, if validated in prospective studies.
本研究的目的是探讨多期磁共振成像(MRI)的相对强化表现,以鉴别透明细胞肾细胞癌(RCC)与其他RCC亚型(乳头状和嫌色细胞型)及嗜酸细胞瘤。
在本研究中,我们纳入了一组病例,包括34例透明细胞RCC、9例嗜酸细胞瘤、12例乳头状RCC和10例嫌色细胞RCC,这些病例均来自2005年至2016年期间接受术前多期动态对比增强MRI检查(最多四期,即平扫、皮质髓质期、肾实质期、排泄期)的患者。对这些组进行多期强化评估,并使用Kruskal-Wallis检验和Mann-Whitney检验进行比较。构建ROC曲线并进行逻辑回归分析,以评估多期强化在鉴别透明细胞RCC与其他三组病变中的表现。
在皮质髓质期,透明细胞RCC与未受累肾皮质相比,相对信号强度显著更高(平均值为2.9),高于嗜酸细胞瘤(-21.7,p = 0.001)、乳头状RCC(-53.0,p < 0.001)和嫌色细胞RCC(-21.0,p < 0.001)。在控制病变大小、患者年龄和患者性别后,皮质髓质期的相对信号强度鉴别透明细胞RCC与嗜酸细胞瘤的曲线下面积(AUC)为0.90,准确率为84%(32/38),敏感性为90%(27/30),特异性为63%(5/8)。在控制病变大小、患者年龄和患者性别后,皮质髓质期相对信号强度鉴别透明细胞RCC与嗜酸细胞瘤及其他RCC亚型的AUC为0.93,准确率为90%(53/59),敏感性为90%(27/30),特异性为90%(26/29)。
如果在前瞻性研究中得到验证,多期MRI强化可能有助于鉴别透明细胞RCC与嗜酸细胞瘤及其他RCC亚型。